Custom Synthesis Amble Tirzepatide 5mg/10mg/15mg/30mg Vials - GMP Standard

Amble tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This 39-amino acid peptide demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The amble tirzepatide molecule features optimized receptor binding characteristics with greater affinity for GIP receptors while maintaining significant GLP-1 receptor activity. This unique pharmacological profile results in enhanced metabolic effects through complementary mechanisms of action.

Our amble tirzepatide is supplied as lyophilized white powder in pharmaceutical-grade vials (5mg, 10mg, 15mg, 30mg) under strict quality control. Each batch undergoes comprehensive analytical testing including HPLC purity verification (>99%) and mass spectrometry confirmation.

For research purposes only. Not for human consumption. Proper storage at -20°C is recommended for long-term stability. The product should be reconstituted with appropriate sterile solvents immediately before experimental use.

Amble tirzepatide represents a significant advancement in incretin-based research compounds, offering researchers a powerful tool to investigate dual receptor agonism in metabolic disorders. The compound's unique mechanism of action makes it particularly valuable for comparative studies with traditional GLP-1 analogs.